MA65527B1 - Récepteurs antigéniques chimériques possédant une spécificité pour le bcma, et utilisations correspondantes - Google Patents

Récepteurs antigéniques chimériques possédant une spécificité pour le bcma, et utilisations correspondantes

Info

Publication number
MA65527B1
MA65527B1 MA65527A MA65527A MA65527B1 MA 65527 B1 MA65527 B1 MA 65527B1 MA 65527 A MA65527 A MA 65527A MA 65527 A MA65527 A MA 65527A MA 65527 B1 MA65527 B1 MA 65527B1
Authority
MA
Morocco
Prior art keywords
bcma
chimeric antigen
antigen receptors
present
specificity
Prior art date
Application number
MA65527A
Other languages
English (en)
Inventor
Jessica Kirshner
Frank Delfino
David Dilillo
Olga Sineshchekova
Kevin Bray
Thomas Meagher
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA65527B1 publication Critical patent/MA65527B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A61K39/4611—
    • A61K39/4631—
    • A61K39/464417—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'antigène de maturation des cellules b (bcma) est exprimé en surface des plasmocytes malins. La présente invention concerne des récepteurs antigéniques chimériques spécifiques de bcma ainsi que des cellules exprimant de tels récepteurs antigéniques chimériques. Dans certains modes de réalisation, les cellules modifiées exprimant les récepteurs antigéniques chimériques de la présente invention sont capables d'inhiber la croissance de tumeurs exprimant bcma. Les cellules modifiées de l'invention sont utilisables pour le traitement de maladies et d'affections dans lesquelles une stimulation ou une induction de la réponse immunitaire ciblant le bcma est souhaitée et/ou thérapeutiquement bénéfique. Par exemple, les cellules modifiées exprimant les récepteurs antigéniques chimériques spécifiques de bcma de la présente invention sont utilisables pour le traitement de divers cancers, dont le myélome multiple.
MA65527A 2018-07-19 2019-07-18 Récepteurs antigéniques chimériques possédant une spécificité pour le bcma, et utilisations correspondantes MA65527B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862700615P 2018-07-19 2018-07-19

Publications (1)

Publication Number Publication Date
MA65527B1 true MA65527B1 (fr) 2024-05-31

Family

ID=67515170

Family Applications (1)

Application Number Title Priority Date Filing Date
MA65527A MA65527B1 (fr) 2018-07-19 2019-07-18 Récepteurs antigéniques chimériques possédant une spécificité pour le bcma, et utilisations correspondantes

Country Status (29)

Country Link
US (2) US20200023010A1 (fr)
EP (2) EP3823665B1 (fr)
JP (2) JP7404335B2 (fr)
KR (1) KR20210035832A (fr)
CN (1) CN112437671A (fr)
AU (1) AU2019308290A1 (fr)
BR (1) BR112021000919A2 (fr)
CA (1) CA3106612A1 (fr)
CL (2) CL2021000142A1 (fr)
CO (1) CO2021000334A2 (fr)
DK (1) DK3823665T5 (fr)
EA (1) EA202190315A1 (fr)
ES (1) ES2973946T3 (fr)
FI (1) FI3823665T3 (fr)
HR (1) HRP20240494T1 (fr)
HU (1) HUE066474T2 (fr)
IL (1) IL279979A (fr)
LT (1) LT3823665T (fr)
MA (1) MA65527B1 (fr)
MD (1) MD3823665T2 (fr)
MX (1) MX2021000532A (fr)
PH (1) PH12021550036A1 (fr)
PL (1) PL3823665T3 (fr)
PT (1) PT3823665T (fr)
RS (1) RS65384B1 (fr)
SG (1) SG11202100221VA (fr)
SI (1) SI3823665T1 (fr)
WO (1) WO2020018825A1 (fr)
ZA (1) ZA202100107B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240046632A (ko) * 2018-08-01 2024-04-09 난트퀘스트, 인크. 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템
WO2020065330A2 (fr) 2018-09-27 2020-04-02 Autolus Limited Récepteur antigénique chimérique
EP3976653A1 (fr) * 2019-05-30 2022-04-06 Lentigen Technology, Inc. Compositions et méthodes de traitement du cancer par immunothérapie anti-bcma
EP4069373A1 (fr) * 2019-12-06 2022-10-12 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du myélome multiple avec des anticorps bispecifiques anti-bcma x anti-cd3
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
WO2021160120A1 (fr) * 2020-02-13 2021-08-19 北京艺妙神州医药科技有限公司 Optimisation d'un récepteur antigénique chimérique
US20230346734A1 (en) * 2020-04-14 2023-11-02 Julius-Maximilians-Universität Würzburg Combination therapy of atra or other retinoids with immunotherapeutic agents binding to bcma
CN112812186B (zh) * 2021-02-08 2022-07-29 华道(上海)生物医药有限公司 一种抗b细胞成熟抗原的纳米抗体及其应用
CN113109572A (zh) * 2021-04-01 2021-07-13 苏州才博医学科技有限公司 一种检测自体cart细胞体液性免疫原性的方法
CN117730091A (zh) * 2021-04-13 2024-03-19 悟境股份有限公司 改善的嵌合抗原受体及其用途
CN117730145A (zh) * 2021-07-16 2024-03-19 克莱格医学有限公司 嵌合抗原受体
CN115466331B (zh) * 2021-11-18 2023-05-30 合源生物科技(天津)有限公司 靶向bcma的嵌合抗原受体及其应用
CN118696058A (zh) * 2021-12-03 2024-09-24 山东先声生物制药有限公司 抗bcma纳米抗体及其应用
CN113980907B (zh) * 2021-12-24 2022-03-15 山东兴瑞生物科技有限公司 一种抗flt3嵌合抗原受体修饰的t细胞及其在制备治疗aml药物中的应用
AU2023219348A1 (en) * 2022-02-09 2024-08-22 Bar Ilan University Anti-bcma car to target immune-related disorders, compositions and method thereof
WO2023193662A1 (fr) * 2022-04-03 2023-10-12 上海先博生物科技有限公司 Récepteur antigénique chimérique ciblant bcma, et son application
CN117143248A (zh) * 2022-05-24 2023-12-01 合源康华医药科技(北京)有限公司 靶向bcma-cd19的双特异性嵌合抗原受体及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
ATE68013T1 (de) 1985-07-05 1991-10-15 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
JP3015383B2 (ja) 1987-09-11 2000-03-06 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 形質導入した線維芽およびそれらの使用
DE3851153T2 (de) 1987-12-11 1995-01-05 Hughes Howard Med Inst Genetische modifizierung von endothelialen zellen.
WO1989007136A2 (fr) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Hepatocytes modifies et leurs utilisations
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
ES2115662T3 (es) 1990-10-31 1998-07-01 Cell Genesys Inc Modificacion genetica de celulas endoteliales.
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CN1419597A (zh) 2000-02-24 2003-05-21 埃克斯西特治疗公司 细胞的同步刺激和富集
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
SI2374818T1 (sl) 2006-06-02 2013-03-29 Regeneron Pharmaceuticals, Inc. Visokoafinitetna protitelesa za humani IL-6 receptor
PL3214091T3 (pl) 2010-12-09 2019-03-29 The Trustees Of The University Of Pennsylvania Zastosowanie komórek T modyfikowanych chimerycznymi receptorami antygenowymi do leczenia nowotworów
KR101976882B1 (ko) 2011-03-23 2019-05-09 프레드 헛친슨 켄서 리서치 센터 세포 면역요법용 방법 및 조성물
KR102247979B1 (ko) 2012-05-25 2021-05-04 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
ES2878449T3 (es) * 2014-07-24 2021-11-18 2Seventy Bio Inc Receptores antigénicos quiméricos de BCMA
IL297223A (en) * 2015-04-13 2022-12-01 Pfizer Chimeric antigen receptors antigen-directed maturation of b cells
PT3674328T (pt) * 2018-02-01 2024-03-14 Innovent Biologics Suzhou Co Ltd Recetor de antigénio quimérico (car) que se liga a bcma e utilizações do mesmo

Also Published As

Publication number Publication date
ES2973946T3 (es) 2024-06-25
KR20210035832A (ko) 2021-04-01
PT3823665T (pt) 2024-02-26
PH12021550036A1 (en) 2021-09-20
ZA202100107B (en) 2024-07-31
EP3823665B1 (fr) 2024-01-24
US20240325445A1 (en) 2024-10-03
SG11202100221VA (en) 2021-02-25
EA202190315A1 (ru) 2021-04-16
LT3823665T (lt) 2024-02-26
HRP20240494T1 (hr) 2024-07-05
DK3823665T5 (da) 2024-08-19
CN112437671A (zh) 2021-03-02
CL2021000142A1 (es) 2021-07-02
SI3823665T1 (sl) 2024-03-29
WO2020018825A1 (fr) 2020-01-23
CO2021000334A2 (es) 2021-01-29
US20200023010A1 (en) 2020-01-23
CL2022003796A1 (es) 2023-07-07
AU2019308290A1 (en) 2021-02-18
BR112021000919A2 (pt) 2021-04-27
EP4324851A3 (fr) 2024-05-15
MX2021000532A (es) 2021-04-12
CA3106612A1 (fr) 2020-01-23
PL3823665T3 (pl) 2024-06-03
FI3823665T3 (fi) 2024-03-01
EP3823665A1 (fr) 2021-05-26
HUE066474T2 (hu) 2024-08-28
MD3823665T2 (ro) 2024-05-31
IL279979A (en) 2021-03-01
JP7404335B2 (ja) 2023-12-25
RS65384B1 (sr) 2024-04-30
EP4324851A2 (fr) 2024-02-21
DK3823665T3 (da) 2024-03-04
JP2021531004A (ja) 2021-11-18
JP2024028944A (ja) 2024-03-05

Similar Documents

Publication Publication Date Title
MA65527B1 (fr) Récepteurs antigéniques chimériques possédant une spécificité pour le bcma, et utilisations correspondantes
PH12021550031A1 (en) BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
PH12020552116A1 (en) Bispecific anti-psma x anti-cd28 antibodies and uses thereof
WO2019224716A3 (fr) Anticorps spécifiques de gucy2c et leurs utilisations
MA33534B1 (fr) Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine
MA49809A1 (fr) Composés utilisés comme inhibiteurs de kinase
RS20100366A (en) IMMUNOGLOBULIN OPTIONS AND THEIR USE
DE602005016773D1 (de) Antikrebs-antikörper mit reduzierter komplementfixierung
MA30358B1 (fr) Quinazolines pour l'inhibition de pdk1
MA35173B1 (fr) Anticorps anti-cxcr4 ayant des fonctions effectrices et son utilisation pour le traitement du cancer
MA47221A1 (fr) Anticorps monoclonal à pd-l1
NO20055741D0 (no) Nye kjemiske forbindelser
MA44227B1 (fr) Anticorps pour il-17c
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
CR20220523A (es) Anticuerpos anti-sea de muc1
MX2021015501A (es) Anticuerpos y metodos de uso.
MX2023006649A (es) Anticuerpos contra interleucina-22.
WO2022271771A3 (fr) Ciblage thérapeutique de la cadhérine 11 dans le cancer
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation
MX2022013176A (es) Anticuerpos anti cumulo de diferenciacion 19 (cd19) y sus usos.
MX2022008391A (es) Anticuerpos epiteliales específicos de cadherina.
MA51297B1 (fr) Quinazolinones en tant qu'inhibiteurs de parp14
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MA42523B1 (fr) Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations